SATURDAY, SEPTEMBER 6, 2025
BREAST CANCER
Education – Learning from the Best
Chair: T. Schnitzbauer
08.15 am
High-Risk Patients: Surgical Perspectives
n.n.
08.25 am
Safety of Lipofilling in Breast Cancer Surgery
V. Bjelic-Radisic
08.35 am
Surgical Strategy for Young Breast Cancer Patients
M. Banys-Paluchowski
Satellite Symposium
Chair: S. Kümmel
A Panoptic View: From Early Detection to Metastasis in HR+/HER2- Breast Cancer
08.45 am
Case Introduction
S. Kümmel
08.50 am
Early Detection, Recurrence Risk – Therapeutic Implications?
P. A. Fasching
09.05 am
Visceral Metastasis – What Now?
M. Banys-Paluchowski
09.20 am
Panel Discussion and Closing
M. Banys-Paluchowski
With the kind support of Novartis Pharma GmbH
09.30 am
Coffee Break
Update on Systemic Treatment in Breast Cancer:
What is Proven, What is Coming Next?
What is Proven, What is Coming Next?
Chair: S. Kümmel, S. Gipe
10.00 am
Triple-Negative Breast Cancer – From Early to Metastatic Disease
P. Schmid
10.20 am
HER2/neu-Positive Disease – From Early to Metastatic Disease
R. Bartsch
10.40 am
HR-Positive Early Breast Cancer – Who Needs Chemotherapy?
O. Gluz
11.00 am
HR-Positive Metastatic Breast Cancer – Which Drugs and When?
N. Harbeck
11.20 am
Live Discussion and Live Chat
S. Kümmel, S. Gipe, P. Schmid, R. Bartsch, O. Gluz, N. Harbeck
Scientific Symposium
Chair: S. Kümmel
ADCs Debut in 1st Line mBC: Navigating Sequencing Challenges
11.40 am
Setting New Standards for HER2+ 1st Line
N. Harbeck
12.10 pm
ADCs in HR+: State of the Art, Sequencing Future Trends
P. Schmid
With the kind support of Daiichi Sankyo Deutschland GmbH
12.40 pm
Lunch Break
Local Therapy I – Axilla Surgery
Chair: S. Gipe, A. S. Caudle, W. P. Weber
01.30 pm
Clinically Negative Axilla: Primary or After Neoadjuvant Systemic Therapy – What is Standard and What Questions Remain Unanswered?
S. Kümmel
01.50 pm
After SOUND and INSEMA Trials – Where We Are? No Surgery or No Radiotherapy?
S. Gipe
02.10 pm
Clinically Positive Axilla: Who Needs Axillary Clearance? Is It More Complicated than Positive or Negative?
A. S. Caudle
02.30 pm
Live Discussion and Live Chat
S. Gipe, A. S. Caudle, W. P. Weber, S. Kümmel
Local Therapy II
Chair: J. Heil, T. Schnitzbauer, A. S. Caudle
02.45 pm
Residual Nodal Disease: Real-World Studies Help when Results from Randomized Trials are Pending
W. P. Weber
03.05 pm
Surgery of the Primary Tumour at Stage IV Disease – Where Are We?
S. Kümmel.
03.25 pm
Local Therapy at Oligoprogression: Surgery? Radiotherapy? Both? – Or Only Change of Systemic Therapy?
M. Reinisch
03.40 pm
Live Discussion and Live Chat
J. Heil, T. Schnitzbauer, A. S. Caudle, W. P. Weber, M. Reinisch
04.00 pm
End of Event
Status: August 2025; program topics and times may be subject to change
